The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes

Oncotarget

Volumn 3, Issue 7, 2012, Pages 700-708

  Singhal, Ruchi ^a   Kandel, Eugene S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

AZD6244; BRAF; Colon cancer; GDC 0879; IPA3; KRAS; Melanoma; NRAS; PAK1

Indexed keywords

2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; ANTINEOPLASTIC AGENT; B RAF KINASE; IPA 3; K RAS PROTEIN; P21 ACTIVATED KINASE 1; RAS PROTEIN; SELUMETINIB; UNCLASSIFIED DRUG;

ARTICLE; BRAF GENE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER STAGING; COLON CARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; INHIBITION KINETICS; MELANOMA; MOLECULAR EVOLUTION; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

EID: 84868626073     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.587     Document Type: Article

References (44)

1. Maurer G, Tarkowski B and Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene. 2011; 30(32):3477-3488.
2. Ribas A and Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nature reviews Clinical oncology. 2011; 8(7):426-433.
3. Alsina J, Gorski DH, Germino FJ, Shih W, Lu SE, Zhang ZG, Yang JM, Hait WN and Goydos JS. Detection of Mutations in the Mitogen-Activated Protein Kinase Pathway in Human Melanoma. Clinical Cancer Research. 2003; 9(17):6419-6425.
4. Goydos JS, Mann B, Kim HJ, Gabriel EM, Alsina J, Germino FJ, Shih W and Gorski DH. Detection of B-RAF and N-RAS mutations in human melanoma. Journal of the American College of Surgeons. 2005; 200(3):362-370.
5. Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino MC, Travali S and McCubrey JA. Analysis of BRAF mutation in primary and metastatic melanoma. Cell cycle (Georgetown, Tex. 2005; 4(10):1382-1384.
6. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging. 2011; 3(3):192-222.
7. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. The New England journal of medicine. 2012; 366(8):707-714.
8. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A and Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468(7326):973-977.
9. Kichina JV, Goc A, Al-Husein B, Somanath PR and Kandel ES. PAK1 as a therapeutic target. Expert Opin Ther Targets. 2010; 14(7):703-725.
10. Martin GA, Bollag G, McCormick F and Abo A. A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20. The EMBO journal. 1995; 14(9):1970-1978.
11. Nheu T, He H, Hirokawa Y, Walker F, Wood J and Maruta H. PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Cell cycle (Georgetown, Tex. 2004; 3(1):71-74.
12. Tang Y, Chen Z, Ambrose D, Liu J, Gibbs JB, Chernoff J and Field J. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol. 1997; 17(8):4454-4464.
13. Somanath PR, Vijai J, Kichina JV, Byzova T and Kandel ES. The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt. Oncogene. 2009; 28(25):2365-2369.
14. Bokoch GM, Reilly AM, Daniels RH, King CC, Olivera A, Spiegel S and Knaus UG. A GTPase-independent mechanism of p21-activated kinase activation. Regulation by sphingosine and other biologically active lipids. The Journal of biological chemistry. 1998; 273(14):8137-8144.
15. Zhou GL, Zhuo Y, King CC, Fryer BH, Bokoch GM and Field J. Akt phosphorylation of serine 21 on Pak1 modulates Nck binding and cell migration. Molecular and cellular biology. 2003; 23(22):8058-8069.
16. King CC, Gardiner EM, Zenke FT, Bohl BP, Newton AC, Hemmings BA and Bokoch GM. p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1). The Journal of biological chemistry. 2000; 275(52):41201-41209.
17. Papakonstanti EA and Stournaras C. Association of PI-3 kinase with PAK1 leads to actin phosphorylation and cytoskeletal reorganization. Mol Biol Cell. 2002; 13(8):2946-2962.
18. Tang Y, Zhou H, Chen A, Pittman RN and Field J. The Akt proto-oncogene links Ras to Pak and cell survival signals. The Journal of biological chemistry. 2000; 275(13):9106-9109.
19. Beeser A, Jaffer ZM, Hofmann C and Chernoff J. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. The Journal of biological chemistry. 2005; 280(44):36609-36615.
20. Tran NH, Wu X and Frost JA. B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. The Journal of biological chemistry. 2005; 280(16):16244-16253.
21. Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J and Peterson JR. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol. 2008; 15(4):322-331.
22. Flaiz C, Chernoff J, Ammoun S, Peterson JR and Hanemann CO. PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Experimental neurology. 2009; 218(1):137-144.
23. Takahashi K and Suzuki K. Membrane transport of WAVE2 and lamellipodia formation require Pak1 that mediates phosphorylation and recruitment of stathmin/Op18 to Pak1-WAVE2-kinesin complex. Cellular signalling. 2009; 21(5):695-703.
24. Ye DZ, Jin S, Zhuo Y and Field J. p21-Activated kinase 1 (Pak1) phosphorylates BAD directly at serine 111 in vitro and indirectly through Raf-1 at serine 112. PloS one. 2011; 6(11):e27637.
25. Wang Z, Oh E, Clapp DW, Chernoff J and Thurmond DC. Inhibition or ablation of p21-activated kinase (PAK1) disrupts glucose homeostatic mechanisms in vivo. The Journal of biological chemistry. 2011; 286(48):41359-41367.
26. Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, Turley H, O'Brien T, Vucic D, Harris AL, Belvin M, Friedman LS, Blackwood EM, Koeppen H and Hoeflich KP. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(17):7177-7182.
27. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer research. 2002; 62(23):6997-7000.
28. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, Houghton AN, Busam K and Polsky D. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer research. 2003; 63(14):3955-3957.
29. Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS and Belvin M. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer research. 2009; 69(7):3042-3051.
30. Gurova KV, Kwek SS, Koman IE, Komarov AP, Kandel E, Nikiforov MA and Gudkov AV. Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor. Cancer biology & therapy. 2002; 1(1):39-44.
31. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR and Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006; 439(7074):358-362.
32. Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA and Fagin JA. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. The Journal of clinical endocrinology and metabolism. 2008; 93(6):2194-2201.
33. Amaria RN, Lewis KD and Gonzalez R. Therapeutic options in cutaneous melanoma: latest developments. Therapeutic Advances in Medical Oncology. 2011; 3(5):245-251.
34. Frost JA, Xu S, Hutchison MR, Marcus S and Cobb MH. Actions of Rho family small G proteins and p21-activated protein kinases on mitogen-activated protein kinase family members. Molecular and cellular biology. 1996; 16(7):3707-3713.
35. Gallagher ED, Xu S, Moomaw C, Slaughter CA and Cobb MH. Binding of JNK/SAPK to MEKK1 is regulated by phosphorylation. The Journal of biological chemistry. 2002; 277(48):45785-45792.
36. Deacon K, Mistry P, Chernoff J, Blank JL and Patel R. p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol Biol Cell. 2003; 14(5):2071-2087.
37. Jakobi R, Moertl E and Koeppel MA. p21-activated protein kinase gamma-PAK suppresses programmed cell death of BALB3T3 fibroblasts. The Journal of biological chemistry. 2001; 276(20):16624-16634.
38. Schurmann A, Mooney AF, Sanders LC, Sells MA, Wang HG, Reed JC and Bokoch GM. p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Molecular and cellular biology. 2000; 20(2):453-461.
39. Jin S, Zhuo Y, Guo W and Field J. p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association. The Journal of biological chemistry. 2005; 280(26):24698-24705.
40. Friedland JC, Lakins JN, Kazanietz MG, Chernoff J, Boettiger D and Weaver VM. alpha6beta4 integrin activates Rac-dependent p21-activated kinase 1 to drive NF-kappaB-dependent resistance to apoptosis in 3D mammary acini. J Cell Sci. 2007; 120(PART 20):3700-3712.
41. Higuchi M, Onishi K, Kikuchi C and Gotoh Y. Scaffolding function of PAK in the PDK1-Akt pathway. Nat Cell Biol. 2008; 10(11):1356-1364.
42. Kandel ES and Stark GR. (2003). Forward genetics in mammalian cells. In: Sehgal PB, Levy DE and Hirano T, eds. Signal Transducers and Activators of Transcription (STATs): Activation and Biology. (The Netherlands: Kluwer Academic Publishers).
43. Ong CC, Jubb AM, Zhou W, Haverty PM, Harris AL, Belvin M, Friedman LS, Koeppen H and Hoeflich KP. p21-activated kinase 1: PAK'ed with potential. Oncotarget. 2011; 2(6):491-496.
44. Kandel ES, Chang BD, Schott B, Shtil AA, Gudkov AV and Roninson IB. Applications of green fluorescent protein as a marker of retroviral vectors. Somatic cell and molecular genetics. 1997; 23(5):325-340.